12 results
8-K
EX-99.2
PASG
Passage Bio Inc
14 May 24
Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
7:01am
in Patients 2 and 3, who received revised steroid regimen following protocol amendment No serious AEs All AEs mild to moderate in intensity No evidence
8-K
EX-99.2
PASG
Passage Bio Inc
4 Mar 24
Passage Bio Reports Fourth Quarter and Full-year 2023 Financial Results and Provides Recent Business Highlights
7:02am
in intensity No evidence of clinically significant immune response, hepatotoxicity or venous sinus thrombosis No evidence of DRG toxicity No complications
8-K
EX-99.1
PASG
Passage Bio Inc
5 Jan 24
Regulation FD Disclosure
4:05pm
protocol amendment No serious AEs All AEs mild to moderate in intensity No evidence of clinically significant immune response, hepatotoxicity or venous
424B1
PASG
Passage Bio Inc
22 Jan 21
Prospectus with pricing info
4:31pm
pathophysiology. Recent brain MRI studies of infants with infantile Krabbe have shown predominance of increased intensity in the dentate/cerebellar
DRS
d2mc6tgn wisg
18 Dec 20
Draft registration statement
12:00am
424B4
qj0e45dgg72tap
28 Feb 20
Prospectus supplement with pricing info
4:07pm
S-1
byfvr2o
3 Feb 20
IPO registration
6:39am
DRS/A
ab4v0m40 44b26ubdwr
10 Jan 20
Draft registration statement (amended)
12:00am
DRS
cqflfsz0ymopjwkcp9
6 Dec 19
Draft registration statement
12:00am
- Prev
- 1
- Next